Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780198 | 0.87 | NPC1 (0.50) | NPC1RAB9ARUNX1CCR1CCR5 | |
| SCHEMBL5379182 | 0.83 | SYK (0.56) | NPC1RAB9ARUNX1CCR1CCR5 | |
| SCHEMBL30525959 | 0.83 | SYK (0.56) | NPC1RAB9ARUNX1CCR1CCR5 | |
| SCHEMBL5326831 | 0.83 | IDH1 (0.58) | NPC1RAB9ARUNX1CCR1CCR5 | |
| SCHEMBL29496938 | 0.83 | SYK (0.56) | NPC1RAB9ARUNX1CCR1CCR5 | |
| SCHEMBL10560080 | 0.82 | NPC1 (0.49) | NPC1RAB9ARUNX1CCR1CCR5 | |
| SCHEMBL17751232 | 0.82 | HSP90AA1 (0.52) | NPC1RAB9ARUNX1CCR1CCR5 | |
| SCHEMBL17069071 | 0.81 | CLK4 (0.53) | NPC1RAB9ACCR1CCR5CCR8 | |
| SCHEMBL12946320 | 0.81 | SYK (0.50) | NPC1RAB9ARUNX1CCR1CCR5 | |
| SCHEMBL29496943 | 0.80 | SYK (0.56) | NPC1RAB9ARUNX1CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019238067-A1 | PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2019-12-19 | — | — | WO | disclosed |
| EP-2802594-B1 | METAL COMPLEXES WITH DIBENZO[F,H]QUINOXALINES | UDC IRELAND LTD (IE) | 2017-04-19 | — | — | EP | disclosed |
| EP-1966343-B1 | ELECTROLUMINESCENT METAL COMPLEXES WITH TRIAZOLES | UDC IRELAND LTD (IE) | 2017-04-19 | — | — | EP | disclosed |
| US-8680760-B2 | Beta-diketone ancillary ligands and their metal complexes used in organic optoelectronic devices | NATIONAL TSING HUA UNIVERSITY (TW) | 2014-03-25 | — | — | US | disclosed |
| US-8017774-B2 | Producing method for iridium complex | CANON KABUSHIKI KAISHA (JP) | 2011-09-13 | — | — | US | disclosed |
| WO-2008024953-A2 | TRANSITION METAL-CATALYZED ALKYLATION OF C-H BONDS WITH ORGANOBORON REAGENTS | BRANDEIS UNIVERSITY (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024953-A2 | TRANSITION METAL-CATALYZED ALKYLATION OF C-H BONDS WITH ORGANOBORON REAGENTS | BRANDEIS UNIVERSITY (US) | 2008-02-28 | — | — | WO | disclosed |
| US-20070232803-A1 | PRODUCING METHOD FOR IRIDIUM COMPLEX | CANON KABUSHIKI KAISHA (JP) | 2007-10-04 | — | — | US | disclosed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2004046103-A2 | ARYLPYRIDINE COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232803-A1 | PRODUCING METHOD FOR IRIDIUM COMPLEX | LAGE3, EML4, INTS9 | NPC1 3553/4885RAB9A 1578/4885RUNX1 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.